Analyzing Esperion Therapeutics (ESPR) and The Competition
Esperion Therapeutics (NASDAQ: ESPR) is one of 196 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare Esperion Therapeutics to similar businesses based on the strength of its risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.
Institutional & Insider Ownership
83.3% of Esperion Therapeutics shares are held by institutional investors. Comparatively, 47.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 32.5% of Esperion Therapeutics shares are held by company insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Esperion Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Esperion Therapeutics Competitors||-3,680.23%||-415.63%||-47.84%|
Volatility & Risk
Esperion Therapeutics has a beta of 2.69, indicating that its share price is 169% more volatile than the S&P 500. Comparatively, Esperion Therapeutics’ peers have a beta of 1.67, indicating that their average share price is 67% more volatile than the S&P 500.
This is a breakdown of recent ratings and target prices for Esperion Therapeutics and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Esperion Therapeutics Competitors||785||2925||6381||144||2.57|
Esperion Therapeutics currently has a consensus price target of $55.21, suggesting a potential upside of 6.31%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 10.39%. Given Esperion Therapeutics’ peers higher probable upside, analysts plainly believe Esperion Therapeutics has less favorable growth aspects than its peers.
Earnings and Valuation
This table compares Esperion Therapeutics and its peers revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Esperion Therapeutics||N/A||-$131.29 million||-8.98|
|Esperion Therapeutics Competitors||$207.14 million||-$2.51 million||0.26|
Esperion Therapeutics’ peers have higher revenue and earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.